The Australian Centre for the Prevention of Cervical Cancer (ACPCC), a not-for-profit organisation with 60 years of expertise in cervical cancer prevention, has partnered with Cirdan to implement a state-of-the-art laboratory information management system (LIMS) to optimise and future-proof its laboratory workflows.
Implementation will occur throughout 2024, across the pathology division of ACPCC - VCS Pathology - in Melbourne. The implementation of Cirdan’s modern and unified LIMS will serve to improve ACPCC’s laboratory efficiency by more effectively managing the flow of samples and data, and ultimately creating a centralised storage of data required for quality control compliance.
ACPCC’s vision and commitment is to prevent cancer and infectious diseases through excellence in the provision of public health services supporting screening, population-based testing and vaccination. As part of its commitment, ACPCC continues to work with Australian and international partners to achieve the World Health Organization’s goal of eliminating cervical cancer as a public health problem, primarily through screening, establishment of screening and vaccination registries and laboratory strengthening.
ACPCC was attracted to Cirdan’s LIMS offering due to its ability to collect high volumes of data in a Lean and expeditious way, to help reduce the time taken for patient diagnosis. The system will provide new insights into healthcare data through its ability to modernise and standardise ACPCC’s pathology workflows and processes.
The new unified single LIMS system will integrate the functionality of various existing subsystems including ACPCC’s current LIMS soution which was developed in-house, a third-party LIMS, scanning and billing solutions as well as services that allow for the communication between internal systems, instruments, and external clients. The implementation of Cirdan’s ULTRA LIMS will future-proof VCS Pathology by creating a completely digital environment, with effective sample and data management enhancing the functionality of ACPCC’s pathology workflows.
Associate Professor Dave Hawkes, Director Molecular Microbiology at ACPCC, commented: “The introduction of the new Cirdan LIMS will allow us to continue to build our versatility whilst maintaining our high quality approach to reporting patients pathology results.”
Speaking about the new partnership, Hugh Cormican, CEO at Cirdan, added: “We are delighted to work with ACPCC, a global leader in the prevention of cervical cancer, and support its tremendous work in Australia and in the wider world.”